logo-loader
viewBoston Scientific

Boston Scientific rises as preliminary 4Q sales figures match consensus estimate

For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion

A surgeon putting on gloves
For all of 2018, Boston Scientific reported a 8.6% gain in preliminary sales

Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.

The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
 
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.

Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Boston Scientific

Price: 43.26 USD

NYSE:BSX
Market: NYSE
Market Cap: $60.3 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fidelity Minerals sees exciting road ahead for company with...

Fidelity Minerals (CVE: FMN) CEO Ian Graham joined Steve Darling from Proactive Vancouver on Skype to provide a corporate update. Graham discussed the latest on the recent sale of their Cerro Dorado asset and why they decided to do a share consolidation. Graham also discusses the shift in...

1 hour, 59 minutes ago

2 min read